IVF After Two Miscarriages: When Genetics and Uterine Tests Are Useful

A review should record the dates of losses, ultrasound findings when available, whether a pregnancy was intrauterine and whether tissue was examined. Early biochemical pregnancies and later clinically documented miscarriages provide different kinds of information. Details of previous pregnancies, age and medications help the specialist decide what to evaluate. Bring any pathology or chromosome reports without assuming their results determine future chances; a genetic finding in one loss does not explain every loss automatically.

Potential investigations include careful history, appropriate uterine-cavity assessment and selected antiphospholipid antibody testing when indicated by guidelines and clinical context. Abnormal tests may need confirmation at a specified interval rather than being treated after a single borderline result. Extensive inherited thrombophilia or immune testing is not routinely helpful for every patient. Ask which results would change medical management and which investigations are mainly unlikely to provide an actionable answer.

Parental karyotyping or other genetic evaluation may be considered selectively, especially when pregnancy tissue results or family history point toward a structural rearrangement. PGT-M and PGT-SR address specific inherited indications and are not the same as PGT-A screening for chromosome number. ASRM guidance does not establish routine PGT-A as a reliable way to improve live birth for everyone with RPL. Genetic counselling can help explain what a test detects and what an inconclusive result would mean.

Some causes of recurrent loss have well-established care pathways; others remain uncertain. Aspirin, anticoagulants, steroids, intralipids and broad immune protocols should not be taken automatically after unexplained losses. The treating clinician should document the diagnosis and evidence before prescribing any intervention. Patients also need compassionate care and an appropriate early-pregnancy monitoring plan; repeated testing without clear use can create harm, cost and additional distress.

IVF may be indicated for infertility, genetic reasons or other reproductive factors, but recurrent pregnancy loss alone does not automatically make IVF superior to trying without assisted reproduction. Age, available embryos, reproductive preferences and emotional circumstances change the discussion. If PGT-A is offered, request realistic counselling about biopsy, no-result findings, possible embryo non-transfer and the distinction between per-transfer outcomes and the cumulative chance of a baby.

Medical records can be organized for a clinician-led remote opinion where available, and selected routine blood tests may be collected at home if a verified service exists. Imaging of the uterus, embryo procedures and specialist emergency assessment remain facility-based. Seek urgent medical care for heavy bleeding, severe abdominal pain, fainting or symptoms of ectopic pregnancy. Ask who will coordinate early scans and how findings are communicated to the responsible obstetric team.

Putting the decision together. Start by asking what would be different if the answer to “start by defining the previous pregnancies?” changed. Then compare that with “do not confuse a possible cause with proven treatment?” in the actual medical record. These questions should lead to a clear choice: proceed with the current plan, obtain a targeted missing result, consider a clinically appropriate alternative, or pause for specialist review. They should not become a standing order for every available fertility test. The clinician should document any uncertainty that remains, because good care is not the same as claiming complete predictability.

Two patients searching for the same term may need very different care. One may require focused diagnostic clarification while another already has enough information to decide between treatment options. The clinician should state the expected benefit of every proposed step and what alternative exists. Records from previous cycles often answer more questions than buying a new panel of tests simply because the old provider used a different name for it.

HomeIVF is a doctor-led model for fertility and IVF care that aims to reduce unnecessary clinic visits, not a way to perform IVF laboratory procedures inside a home. Where a responsible clinician judges it suitable and the actual address is supported, a teleconsultation, selected home blood collection or supervised injection assistance may be arranged. Availability, collection timing, staff qualifications and charges must be confirmed rather than assumed. Medically indicated ultrasound scans, egg retrieval, IUI procedures, sperm preparation, embryo culture, genetic testing and embryo transfer remain facility-based. The clinician supervising treatment must be able to respond to results and complications.

Before accepting a remote-care plan, ask the treating clinician to identify each event that requires in-person assessment. This may change between cycles as scan results, ovarian response or symptoms change. Some steps can be coordinated by telephone or video, but procedure-day decisions belong to the appropriately equipped fertility team. Written consent and a transparent escalation route make flexible care safer.

Choose the next step by asking whether it is necessary now, what evidence supports it and what happens if it is deferred. Treatment estimates can change when stimulation response, test results or laboratory findings differ from expectations. Confirm refund, cancellation and storage policies before payment. Most importantly, do not interpret a low advertised price as evidence of quality, or a high price as a guarantee.